Facilitated Percutaneous Coronary Intervention  by Borden, William B. & Faxon, David P.
F
W
C
D
a
o
(
4
u
s
s
i
m
u
(
b
c
a
w
R
t
s
b
p
t
w
b
e
i
s
t
o
C
Journal of the American College of Cardiology Vol. 48, No. 6, 2006
© 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00
Pacilitated Percutaneous Coronary Intervention
illiam B. Borden, MD, David P. Faxon, MD
hicago, Illinois
The goal of the initial treatment for ST-segment elevation myocardial infarction is rapid and
effective reperfusion. Randomized trials have demonstrated that primary angioplasty is
preferred over thrombolysis if done in a timely manner and by an experienced team. However,
due to many factors, performance of primary angioplasty within the goal of 90 min is often
not possible. A combined strategy of immediate thrombolysis in the emergency room or in
the ambulance followed by angioplasty theoretically could provide early reperfusion with
subsequent angioplasty to insure complete reperfusion. Over 17 clinical trials have been
reported. Compared with thrombolysis, facilitated angioplasty in the most recent trials has
been shown to have a more favorable long-term outcome. Trials comparing facilitated
angioplasty with full- or half-dose thrombolysis versus primary angioplasty have been far less
favorable with the largest trial to date, the ASSENT (Assessment of the Safety and Efficacy
of a New Treatment Strategy with Percutaneous Coronary Intervention)-4 trial, demonstrat-
ing a worse outcome in the primary end point of death, congestive heart failure, or shock at
90 days. Pending the results of the FINESSE (Facilitated Intervention with Enhanced
Reperfusion Speed to Stop Events) trial, current data suggest that facilitated angioplasty does
not offer any advantage over primary angioplasty and may be harmful. (J Am Coll Cardiol
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.03.0622006;48:1120–8) © 2006 by the American College of Cardiology Foundation
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pespite dramatic improvements in the care for coronary
rtery disease in the last 25 years, an estimated 1.3 million
r more Americans will have acute myocardial infarctions
AMIs) in 2006. The impact of such a high incidence is that
0% of those who experience an AMI in a given year will
ltimately die from their coronary artery disease (1). A
ubstantial proportion of these AMIs are due to ST-
egment elevation AMI (STEMI) (2). A wealth of random-
zed controlled trials now guides physicians as to the
edical and interventional management of STEMI, partic-
larly in facilities where percutaneous coronary intervention
PCI) is available. However, there remains a chasm in care
etween those patients presenting with AMI to a PCI-
apable hospital compared with those patients presenting to
facility without such resources.
The essential goal of care for AMI remains reperfusion
ith either a thrombolytic infusion or with rapid PCI.
andomized controlled trials involving thousands of pa-
ients as well as registry data have convincingly demon-
trated that, when available, timely PCI confers a mortality
enefit of 25% to 30% (3,4). However, when a patient
resents early in the course of their symptoms, the rapid
iming of PCI remains critical. With the conceptual frame-
ork that “time delay equals myocardium lost,” the goal has
een to achieve reperfusion as quickly as possible because
ach 30-min delay in reperfusion results in a 7.5% increase
n 1-year mortality (5,6). When weighing the choice of
trategy, delays in door-to-balloon time for PCI greater
han 1 h over when thrombolytic reperfusion would have
ccurred may negate the mortality benefit of PCI (7). The
From the Section of Cardiology, Department of Medicine, University of Chicago,m
hicago, Illinois.
Manuscript received March 24, 2006, accepted March 30, 2006.trongest predictor of a delay is the need for transfer to a
CI-capable hospital (7,8).
Even though transfer is a potential delay, multiple studies
ave demonstrated safety with transporting AMI patients
or PCI and, as a whole, the data demonstrate a reduction in
eath/re-infarction/stroke of 42% (9–15). In all of these
tudies, the transport time was3 h, and often90 min—a
esult that may not be realistically applied generally, where
ystematic factors may complicate such rapid transport.
hus, a combination strategy, referred to as “facilitated
CI,” may confer benefit by providing early, though poten-
ially partial, flow with thrombolytics followed by transfer
or PCI to complete and sustain the reperfusion (16–18).
he American Heart Association/American College of
ardiology (AHA/ACC) guidelines for the management of
TEMI designate facilitated PCI as a class IIb recommen-
ation with level of evidence B, stating, “Facilitated PCI
ight be performed as a reperfusion strategy in higher-risk
atients when PCI is not immediately available and bleed-
ng risk is low (19).” Thus, there is still ambiguity in the
uidelines about the utility of facilitated PCI.
While the AHA/ACC guidelines use a broad definition,
his review will focus only on facilitated PCI that involves
harmacologic thrombolysis followed by transport for im-
ediate or early mechanical reperfusion with percutaneous
ransluminal coronary angioplasty (PTCA) and/or stenting.
ther strategies such as rescue PCI (intervention after failed
hrombolysis with recurrent symptoms, sustained ST-
egment elevations, or cardiogenic shock) or adjuvant phar-
acologic therapy with glycoprotein IIb/IIIa inhibitors will
ot be addressed in this article (20–25).
Articles for review were identified by searching the
ubMed database using the keywords “facilitated angio-
lasty” and “facilitated PCI.” Abstracts from the 2005 AHA
eeting were searched. Further papers were found by
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earch resulted in 5 major groupings of studies: early trials,
tudies of thrombolytics alone versus of thrombolytics and
CI, and studies of PCI alone versus thrombolytics and
CI, meta-analyses, and latest trials.
ARLY TRIALS
ith the initial trials of PTCA versus thrombolytics in
MI, there was the recognition that time was essential and
hat there could be potential synergistic benefits to combin-
ng the rapidity of thrombolysis and the improved reperfu-
ion of PTCA. Thus, some of these early studies in the late
980s and early 1990s examined the role of facilitated PCI
n the pre-stent era.
The TAMI (Thrombolysis and Angioplasty in Myocar-
ial Infarction) study randomized 197 AMI patients after
eceiving intravenous tissue plasminogen activator (t-PA) to
ither immediate PTCA or to deferred PTCA (26,27).
ith the exception of a higher rate of emergent PCI in the
eferred PTCA group (16% vs. 5%; p  0.01), there were
o differences in outcomes between the 2 groups. A second,
maller study, took patients who had been randomized to
ither t-PA or placebo to the catheterization laboratory and
urther randomized those in the t-PA group with 50%
tenosis to either PTCA or no PTCA (28). The only
ifference between the groups was an improvement in
nfarct-zone regional wall motion in the combined t-PA
nd PTCA group. These 2 initial studies demonstrated
gain the increased vessel patency after t-PA, but showed
nly minimal or no benefit to subsequent emergent angio-
lasty after t-PA.
A substudy of the Thrombolysis In Myocardial Infarction
TIMI)-II study entitled TIMI-IIA examined the role of
mmediate compared with delayed PTCA after t-PA in 389
atients (29,30). This study confirmed the findings of the
arly studies showing no difference in the primary end point
f ejection fraction at 1 year. However, in contrast to the
revious studies, TIMI-IIA did show a significant increase
n complications with the combination of t-PA and imme-
Abbreviations and Acronyms
AHA/ACC  American Heart Association/
American College of Cardiology
AMI  acute myocardial infarction
ECSG  European Cooperative Study Group
PCI  percutaneous coronary intervention
PTCA  percutaneous transluminal coronary
angioplasty
STEMI  ST-segment elevation acute myocardial
infarction
TNK  tenecteplase
t-PA  tissue plasminogen activatoriate PTCA, with higher rates of bleeding (20.0% vs. 7.2%; w 0.001) and coronary artery bypass surgery (16.4% vs.
.7%; p  0.01).
The European Cooperative Study Group (ECSG) sec-
nded the TIMI-IIA concerns about safety of t-PA with
mmediate angioplasty (31). The ECSG study was termi-
ated early due to lack of demonstrated benefit and a
on-significant trend toward increased mortality in the
mmediate invasive group (32). A subgroup analysis of the
CSG study suggested that re-occlusion and re-infarction
ere responsible for the lack of benefit of the early invasive
trategy after t-PA and that perhaps procedural improve-
ents in PTCA would lead to a benefit of immediate
TCA after thrombolysis (33). Similar results were also
ound in a study of streptokinase with and without imme-
iate PTCA with no significant difference in outcome or
ortality (34).
Among these early trials, the TAMI-5 trial provided the
ost substantial support for facilitated PCI with an im-
rovement in wall motion as well as in composite clinical
utcomes without increased complication rates (35). This
tudy, however, was not powered to show mortality benefit
nd excluded many patients with poor prognoses who might
ave benefited from the aggressive strategy. A meta-analysis
f the early trials showed no early mortality benefit to
acilitated PCI; however, there was a cautious suggestion
hat perhaps early PTCA after thrombolytics improved
ortality in the 6- to 52-week window (36). The authors
omment that perhaps the early indifference in mortality
as due to procedural complications, but that survivors of
he initial period had better long-term outcomes with the
arlier aggressive reperfusion strategy. The high bleeding
ates seen in the facilitated group in these trials are note-
orthy given the recognized adverse consequences of bleed-
ng on mortality (37,38).
The early trials left many questions unanswered as to the
enefit of facilitated PCI. While safety concerns lingered,
here were hints in these studies that perhaps the combina-
ion reperfusion approach saved myocardium and, with
echnical improvements of intervention, facilitated PCI
ould perhaps be shown to be a beneficial strategy. Entering
nto the era of stents, improved antiplatelet agents, and
reater operator experience, multiple study groups set forth
o expand on the data provided by the TAMI, TIMI-IIA,
CSG, and TAMI-5 trials.
HROMBOLYTICS VERSUS FACILITATED PCI
n the late 1990s and early 2000s, with the debate still active
ver thrombolysis as opposed to direct PCI for AMI, trials
ere undertaken to examine thrombolysis compared with
he combination approach of facilitated PCI (Table 1).
oreover, these trials served to give important guidance to
ospitals without on-site PCI capability, where physicians
ould give thrombolytics and then debate whether or not to
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Facilitated Percutaneous Coronary Intervention September 19, 2006:1120–8ransport their patients to a tertiary care center for imme-
iate PCI.
Expanding on the concept that facilitated PCI can detect
nd treat those patients whose arteries have failed to fully
e-canalize with thrombolytics, a subgroup analysis of 323
atients in the GUSTO-4 SPEED (Facilitation of Early
ercutaneous Coronary Intervention After Reteplase With
r Without Abciximab in Acute Myocardial Infarction:
esults From the SPEED [GUSTO-4 Pilot]) trial who
nderwent PCI after receiving abciximab with either t-PA
r placebo compared with 162 patients who did not receive
arly PCI (39). While the SPEED trial incorporated
ultiple thrombolytic dosing regimens and had the limita-
ion that the decision to perform PCI was left to the
iscretion of the treating physician, it did show a statistically
ignificant decrease in major clinical outcomes from 29.6%
o 14.6% with PCI compared with no PCI. There was no
ifference in bleeding rates. The authors suggested that the
mprovement stemmed from the use of abciximab, stents,
ppropriate heparinization, and improved operator experi-
nce; however, they cautioned that larger, dedicated studies
ere needed. Those studies would take several years and are
et to be published.
Another retrospective analysis, this one of the TIMI-10B
nd TIMI-14 trials, compared those patients who received
nterventions with those who did not after thrombolysis
40). Patients who received adjunctive PCI, on vessels with
IMI flow grade 2 or 3, had lower rates of death or
ecurrent AMI than those patients who received no inter-
ention and had TIMI flow grade 2 or 3. A non-
andomized prospective study from Japan examined imme-
iate adjuvant PCI after either monteplase or pamiteplase in
atients with either TIMI flow grade 0, 1, or 2 (41). The
tudy showed no differences when patients were segregated
y age range.
The first new randomized prospective study of thrombo-
able 1. Thrombolytic Versus Facilitated PCI
Authors Titles Year Study T
ermeer et al. (12) 1999 Prospective ra
idimsky et al. (13) PRAGUE 2000 Prospective ra
errmann et al. (39) GUSTO-4 SPEED 2000 Retrospective
chweiger et al. (40) TIMI 10B-TIMI 14 2001 Retrospective
cheller et al. (43) SIAM III 2003 Prospective ra
ernandez-Avilés (44) GRACIA-1 2004 Prospective ra
atanabe (41) FAST-3 2004 Registry
e May et al. (45) CAPITAL AMI 2005 Prospective ra
APITAL AMI  Combined Angioplasty and Pharmacological Intervention Vers
tenting trial; GRACIA 1 Routine Invasive Strategy within 24 Hours of Thrombo
T-Segment Elevation trial; GUSTO-4 SPEED  Facilitation of Early Percutaneou
nfarction trial; OR  odds ratio; PCI  percutaneous coronary intervention; PRAG
pecialized PTCA Units with or without Emergency Thrombolysis trial; SIAM  South
hrombolysis in Myocardial Infarction 10B and 14 trials.ytics versus facilitated PCI in the stent era came from the setherlands as part of a transport for AMI study (12).
atients were randomized to 1 of 3 groups: alteplase,
lteplase with transport for PCI, or direct transfer for PCI
ith no thrombolysis. Because this study was designed for
afety and feasibility, it did not show any significant differ-
nces between the groups, though it did confirm previous
tudies demonstrating that there was improved coronary
ow in those patients who had received PCI.
A similar trial was performed in the Czech Republic with
he PRAGUE (PRimary Angioplasty in patients transferred
rom General community hospitals to specialized PTCA
nits with or without Emergency thrombolysis) study
xamining transport and a similar randomization approach
o the Netherlands study (13,42). While also designed for
afety and feasibility, the PRAGUE study randomized 300
atients and was able to demonstrate a significant decrease
n the primary end point of death/re-infarction/stroke with
acilitated PCI compared with thrombolysis alone from 23%
o 15% (p  0.02). However, the study also showed that
ransport for PCI alone, without thrombolysis, led to an
ven lower combined end point of only 8% (p  0.02).
oreover, in the facilitated PCI group, there were signifi-
antly more fatal bleeding complications compared with
ither the thrombolysis or PCI alone groups (7.2% vs. 0%
s. 0%; p  0.001).
The SIAM-III (Southwest German Interventional Study
n Acute Myocardial Infarction) randomized 110 patients
ho had received reteplase to either immediate PCI with
tenting or to the same intervention 2 weeks later (43).
sing a combined primary end point of death, re-infarction,
schemic events, or target lesion revascularization, this study
howed a significant improvement from the thrombolysis
roup of 50.6% to 25.6% in the facilitated PCI group. There
ere no differences in bleeding risks. A major difference
etween the SIAM-III trial and the PRAGUE study was
ime; in the PRAGUE study the median time from admis-
No. of
Patients
Lytic Alone
No. of
Patients
Facilitated
Short-Term
Lytic
Alone
Death
Facilitated p Value
ized 75 74 6.7% 8.1% NS
ized 99 100 14.0% 12.0% NS
162 323 3.7% 3.4% 1.00
738 1,200 OR 0.51 0.09
ized 81 82 9.9% 4.9% 0.179
ized 252 248 2.0% 2.0% 0.84
— — — — —
ized 84 86 3.6% 2.3% 0.68
rombolysis Alone in Acute Myocardial Infarction study; FAST  Femoral Artery
ersus Ischemia-Guided Conservative Approach for Acute Myocardial Infarction with
onary Intervention After Reteplase with or without Abciximab in Acute Myocardial
Primary Angioplasty in Patients Transferred from General Community Hospitals to
erman Interventional Study in Acute Myocardial Infarction; TIMI 10B-TIMI 14 ype
ndom
ndom
ndom
ndom
ndom
us Th
lysis V
s Cor
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west Gion to balloon opening was 108 min, while in the SIAM-
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rom thrombolysis to angiography of 3.5 h.
Recognizing that some of the early trials lacked applica-
ility in current practice, 2 more recent studies looked at
hrombolysis versus modern PCI with the expanded arsenal
f stents and glycoprotein IIb/IIIa inhibitors. The
RACIA-1 trial (Randomized Trial Comparing Stenting
ithin 24 h of Thrombolysis Versus Ischemia-Guided
pproach to Thrombolyzed AMI With ST-Segment Ele-
ation) randomized 500 patients who had received t-PA for
MI to either PCI within 24 h or to a conservative
schemia-guided approach (44). The study showed a 1-year
mprovement in death/re-infarction/revascularization from
1% to 9% in the facilitated PCI group. The CAPITAL
MI (Combined Angioplasty and Pharmacological Inter-
ention Versus Thrombolysis Alone in Acute Myocardial
nfarction) study took the approach of the GRACIA-1 trial
nother step further by using the more effective new
hrombolytic tenecteplase (TNK) with modern PCI (45).
he study enrolled 170 patients and primarily showed a
eduction at 6 months in recurrent unstable ischemia from
0.7% in the TNK group to 8.1% in the facilitated PCI
roup (p  0.03).
Importantly, both the GRACIA-1 and CAPITAL AMI
rials showed no difference in major bleeding complications.
hese larger, more recent trials have helped to understand
hrombolytics versus facilitated PCI. However, the devel-
ping picture that primary PCI, when available, was the
tandard of care set the stage to ask the question of whether
here was benefit when comparing primary PCI to facili-
ated PCI.
CI VERSUS FACILITATED PCI
ome of the trials comparing primary coronary intervention
o facilitated PCI trials overlapped with some of the
hrombolytics versus facilitated PCI trials by consisting of 3
rms: thrombolytics alone, PCI alone, and facilitated PCI.
ue to compelling concerns about the increased bleeding
omplications seen with facilitated PCI, some of the more
able 1. Continued
Short-Term Short
Lytic
Alone
Reinfarction
Facilitated p Value
Lytic
Alone
Revascula
Facili
9.3% 5.4% NS 30.7% 23.0
10.0% 7.0% NS 14.1% 7.0
4.9% 1.2% 0.03 9.3% 1.6
OR 0.45 0.06 — —
2.5% 2.4% 0.685 2.5% 2.4
2.0% 1.0% 0.98 12.0% 2.0
— — — — —
13.3% 4.7% 0.06 50.6% 13.9ecent trials tried to attenuate that risk by varying the bosage of thrombolytics. Thus, some studies examined full-
ose thrombolytics (Table 2) and some examined reduced-
ose thrombolytics (Table 3) in conjunction with PCI
ompared with PCI alone.
ull-dose thrombolytics. Two of the first trials were the
reviously mentioned studies from the Netherlands and
he Czech Republic (12,13). While both of these studies
ocused on safety and feasibility of transport in AMI,
hey did provide insights that there was not a dramatic
enefit to facilitated PCI and, in the PRAGUE study,
hat direct PCI without thrombolytics had better out-
omes as well as fewer complications. Because the initial
RAGUE study found facilitated PCI to be inferior to
ransport for immediate PCI alone, the Czech study
roup did not include facilitated PCI in their follow-up
RAGUE-2 trial (14).
Except for these 2 transport trials, there exists only a
imited amount of recent data regarding facilitated PCI with
ull-dose thrombolytics. A small study from Japan random-
zed 39 patients to either monteplase or placebo before PCI
46). As seen in previous studies, the thrombolytic group
ad greater TIMI flow grade and lower percentage stenosis;
owever, perhaps limited by its size, the study did not
emonstrate any change in follow-up angiography, target
esion revascularization, or in clinical outcomes.
A retrospective study by Möckel et al. (47) looked at their
atients receiving either tirofiban or a variety of fibrinolytics
efore PCI and found both increased rates of both major
leeding and major adverse events with the group of PCI
acilitated by thrombolytics. Two recent abstracts showed a
andomized trial that demonstrated improved ST-segment
ecovery with facilitated PCI compared with either throm-
olytics alone or PCI alone and a retrospective study that
howed no benefit nor harm with facilitated PCI (48,49). In
eneral, the more recent research has focused on reduced-
ose thrombolytics; however, the largest and latest trial of
acilitated PCI with full-dose thrombolytics, ASSENT
Assessment of the Safety and Efficacy of a New Treatment
trategy with Percutaneous Coronary Intervention)-4, will
Short-Term
ion
p Value
Lytic
Alone
Bleeding
Facilitated p Value
NS 11.0% 21.0% Not reported
NS 0.0% 7.2% 0.001
0.001 8.6% 6.5% 0.46
— — — —
0.685 7.4% 9.8% 0.400
0.0001 1.6% 1.6% NS
— — — —
0.001 13.1% 23.3% 0.11-Term
rizat
tated
%
%
%
%
%
%e discussed in the following text (50).
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Facilitated Percutaneous Coronary Intervention September 19, 2006:1120–8educed-dose thrombolytics. Support for reduced-dose
hrombolytics was bolstered with the 1999 publication of
he PACT (Plasminogen Activator-Angioplasty Compati-
ility) trial, testing the hypothesis that a lower-dose of a
hort-acting thrombolytic would attenuate some of the
dverse effects seen in prior trials while maintaining the
enefits of early reperfusion (51). The PACT trial random-
zed 606 patients to either a 50-mg bolus of recombinant
-PA or to placebo followed by urgent PCI. Consistent with
rior studies, there was better initial coronary flow in those
atients who received thrombolytics; however, TIMI flow
rade 3 was equal in the 2 groups after PCI. While overall
easures of left ventricular performance were equal between
he 2 groups, a subgroup analysis showed improved left
entricular function in those who had TIMI flow grade 3 on
nitial images compared with those who had TIMI flow
rade 3 only after intervention. The authors concluded that
heir regimen of a short-acting, fibrin-selective thrombolytic
n reduced dose created earlier revascularization and subse-
uent improved left ventricular performance.
In the interim, while waiting for larger randomized trials,
everal smaller studies were released. Following up on the
rst trial, the GRACIA-2 trial compared facilitated PCI in
he 3- to 12-h window to primary PCI in less than 3 h
52,53). Aside from improved perfusion, no significant
utcome differences were observed between the 2 groups
lthough none of the studies were sized to look at mortality.
owever, with an average time to catheterization of 5.89 h
n the facilitated arm compared with 1.08 h in the primary
CI group, the authors viewed the absence of differences
etween groups as evidence that facilitated PCI was a safe
nd equally effective alternative to primary PCI when
xternal factors such as geographic distance prohibited early
ntervention.
A small registry of 200 patients added more support to
his concept by showing promising outcomes in patients
ransported with a combination of abciximab, reduced doses
f alteplase, and PCI (54). The same group from Poland
ecently reported on a larger registry comparing transferred
acilitated PCI to primary PCI patients and showed similar
linical outcomes, though higher rates of moderate and
able 2. Primary PCI Versus Full-Dose Facilitated PCI
Authors Titles Year Study Ty
ermeer et al. (12) 1999 Prospective rand
idimsky et al. (14) PRAGUE 2000 Prospective rand
urihara et al. (46) 2004 Prospective rand
öckel et al. (47) 2005 Retrospective
SSENT Investigators (50) ASSENT-4 2006 Prospective rand
SSENT  Assessment of the Safety and Efficacy of a New Treatment Strategy wevere bleeding (5.5% vs. 2.3%) and hemorrhagic stroke w0.6% vs. 0.0%), in the facilitated PCI group (55). Another
ransport registry, this time from Minnesota, showed equiv-
lent 30-day outcomes of death, stroke, and re-infarction
etween direct and facilitated PCI, with remarkably short
oor-to-balloon times of 117 min for patients 60 to 200
iles from the interventional center, though bleeding com-
lication data have not been published yet (56).
While these preceding 3 studies have looked at trans-
orting for PCI, another potential advantage with facil-
tated PCI is that, even in an interventional center, using
thrombolytic to create early reperfusion may convert the
mergent need for PCI into an urgent need, thereby
llowing the PCI to occur during daytime hours. Night-
ime presentation for PCI has been associated with worse
utcomes (57). A registry giving facilitated PCI to those
rriving in off hours and direct PCI to those arriving
uring on hours showed with facilitated PCI an improve-
ent in corrected post-intervention TIMI frame count, a
rend toward increased bleeding, and no difference in
rimary clinical outcomes (58). In that study, even the
ff-hours facilitated PCI group had a low door-to-
alloon time of 72 min. An investigation of a longer delay
ompared abciximab, half-dose recombinant t-PA, and
CI in either 2 h, or PCI in the window from 12 to
2 h showed no difference between groups (59). These
tudies suggest that even in centers capable of performing
CI, facilitating PCI through the use of reduced-dose
hrombolytics, may have a role in allowing more time to
erform the intervention, especially in off hours, without
ny worsening of outcomes.
Though many of these studies have shown essential
quivalency of facilitated PCI to direct PCI, 2 more recent
tudies question not only the efficacy of facilitated PCI, but
lso its safety. The ADVANCE MI (ADdressing the Value
f facilitated ANgioplasty after Combination therapy or
ptifibatide monotherapy in acute Myocardial Infarction)
rial sought to enroll 5,640 patients in 30 centers; however,
t was terminated early due to slow recruitment (60). Even
ith its limited enrollment of 148 patients, the primary end
oint at 30 days of death or new/worsening heart failure was
ncreased in the intention-to-treat facilitated PCI arm as
No. of
Patients
Lytic Alone
No. of
Patients
Facilitated
Short-Term
Lytic
Alone
Death
Facilitated p Value
ed 75 74 6.7% 8.1% NS
ed 101 100 7.0% 12.0% NS
ed 20 19 0.0% 0.0% NS
44 35 4.5% 20.9% 0.028
ed 838 829 5.0% 7.0% 0.1412
rcutaneous Coronary Intervention. Other abbreviations as in Table 1.pe
omiz
omiz
omiz
omizas the rate of bleeding complications. Due to the limited
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September 19, 2006:1120–8 Facilitated Percutaneous Coronary Interventionumber of patients in the trial, results must be interpreted
ith caution. However, lack of benefit with facilitated PCI
as also seen by examining infarct size in the 253-patient
RAVE (Bavarian Reperfusion Alternatives Evaluation)
tudy, which randomized patients with abciximab and PCI
o either half-dose reteplase or no thrombolytic (61).
With the wide range of results, no clear conclusions can yet
e drawn from the studies with reduced-dose thrombolytics.
ATEST TRIALS
wo recent trials have sought to definitively answer the
uestion raised by nearly 2 decades of previous studies: is
CI facilitated by thrombolysis safe and effective? The
SSENT-4 PCI trial randomized patients to PCI with or
ithout full-dose TNK with a primary end point of 90-day
eath, cardiogenic shock, or congestive heart failure (50).
fter randomizing 1,667 patients, the trial was terminated
arly in April 2005 by the Data Safety Monitoring Board
ue to worse outcomes observed in the facilitated PCI arm.
he TNK plus PCI patients had significantly higher rates of
epeated myocardial infarction (6% vs. 4%; p  0.0279),
epeat target vessel revascularization (7% vs. 3%; p 
.0041), stroke (1.8% vs. 0%; p  0.0001), and, in the
rimary trial, end point of death, congestive heart failure, or
hock (18% vs. 13%; relative risk 1.3, 95% confidence
nterval 1.11 to 1.74; p  0.0045).
Limitations of the study were that it was stopped before
he pre-specified number of patients was enrolled and that
he randomization-to-balloon times were similar in both
roups at less than 120 min. Potentially, the rapid timing
rom TNK-to-balloon of 104 min played a role in the worse
utcomes, whereas benefit might be seen if there were to be
longer delay between thrombolytic and PCI. Regardless of
hese limitations, the ASSENT-4 trial raises serious con-
erns about continued use of facilitated PCI.
Following up on the ASSENT-4 trial, the FINESSE
Facilitated Intervention with Enhanced Reperfusion Speed
o Stop Events) trial is randomizing patients going for
mmediate PCI to 1 of 3 groups: abciximab plus reduced-
ose reteplase, abciximab alone, or placebo (62). This study
as the additional advantage of investigating a lower-dose
hrombolytic. While results from the FINESSE trial should
able 2. Continued
Short-Term Shor
Lytic
Alone
Reinfarction
Facilitated p Value
Lytic
Alone
Revascul
Facil
1.3% 5.4% NS 6.0% 23
1.0% 7.0% 0.03 6.9% 7
5.0% 5.8% NS 31.6% 17
0.0% 2.9% NS 2.3% 0
4.0% 6.0% 0.0279 3.0% 7e forthcoming, enrollment has not yet completed. The wedical community will have to wait to see whether this
arge, randomized trial confirms the results of the
SSENT-4 trial, or if it demonstrates benefit in the setting
f a reduced-dose thrombolytic.
ETA-ANALYSES
ombining the data from all of the preceding trials presents
daunting task. Aside from the differences in control groups
nd dosing of thrombolytics, the facilitated PCI trials
iffered in type of thrombolytic, the use of glycoprotein
Ib/IIIa inhibitors, the use of stents and other more advance
CI technologies, the timing of the intervention, the
ndications for PCI, and in the outcome measures analyzed.
espite these limitations, 3 meta-analyses attempted to
ollate this plethora of data.
One analysis found equivocal data to support PCI after
hrombolysis, with the later, stent-era trials favoring inter-
ention after thrombolytics (63). This analysis does point
ut that the largest randomized trials showed no benefit to
arly PCI after thrombolysis. A recently presented meta-
nalysis of 5 trials focused on just comparing facilitated PCI
ith primary PCI, and found results consistent with many
f the individual trials: an improvement in TIMI flow grade
upon arrival to the catheterization lab after thrombolytics,
hough no difference in 30-day mortality, and a trend
oward increased major hemorrhage with the facilitated
pproach (64).
Finally, a meta-analysis, incorporating the recent
SSENT-4 trial data, found even worse outcomes with
acilitated PCI (65). While this article analyzed a broader
efinition, including studies of PCI assisted with glyco-
rotein IIb/IIIa, their analysis of 6 trials of thrombolytic-
acilitated PCI did show improved initial TIMI flow grade
in the combination group, though similar TIMI flow
rade 3 after PCI was performed. However, when assess-
ng clinical outcomes, facilitated PCI was associated with
ncreased rates of short-term death (5% vs. 3%; p 
.04), non-fatal MI (3% vs. 2%; p  0.006), and target
essel revascularization (4% vs. 1%; p  0.010). Among
his subgroup of the meta-analysis, there was a non-
ignificant trend toward an increase in major bleeding
m Short-Term
tion
p Value
Lytic
Alone
Bleeding
Facilitated p Value
NS 11.0% 21.0% Not reported
NS 0.0% 7.2% 0.001
NS 0.0% 0.0% NS
NS 2.3% 11.4% NS
0.0041 4.4% 5.6% 0.3118t-Ter
ariza
itated
.0%
.0%
.6%
.0%
.0%ith facilitated PCI.
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he reasoning behind facilitated PCI is sound, and finding
mechanism to achieve the earliest reperfusion is a reason-
ble goal. It seems only logical that achieving temporizing
eperfusion with thrombolytics followed by definitive reper-
usion with PCI would save the most myocardium. The first
ain reason pushing forward the use of facilitated PCI is
he limited access that some areas of the country have to
CI-capable centers. The delay in transport to a hospital
ith interventional capability could mean myocardium lost
nd increased infarct size, an outcome hopefully improved
ith early thrombolytic reperfusion. The second main
riving force pushing forward facilitated PCI is that, even in
enters with 24-h interventional catheterization laborato-
ies, there remain delays in door-to-balloon times, particu-
arly for off hours. National Registry of Myocardial Infarc-
ion data from 2002 suggest that only 37% of patients are
chieving a door-to-balloon time of 90 min (66). An
nfusion of a thrombolytic in the emergency department
ould create enough reperfusion so as to turn back the
icking clock of myocardium being lost, and allow more
ime for either the interventional team to arrive at the
ospital, or potentially, for the patient to await intervention
uring the daytime (18).
The data for facilitated PCI have been mixed at best, and
he more recent trials suggest worse outcomes with facili-
ated PCI. The main drawback, noted in the earliest trials,
as the increased rates of bleeding with the facilitated PCI
pproach. Having thrombolytic agents in the vascular sys-
em followed by an arterial puncture and further anticoag-
lation has led to both minor and major bleeding compli-
ations. After the early trials, some of these bleeding
omplications were decreased, thought to be secondary to
maller sheaths, improved anticoagulation regimens, and
he experimentation with reduced-dose thrombolytics.
owever, the more recent trials, ADVANCE MI and
SSENT-4, have again demonstrated higher bleeding
isks, suggesting that this complication has not gone away.
he association between bleeding, anemia, and transfusion,
nd a poor short- and long-term outcome is strong and
able 3. Primary PCI Versus Reduced-Dose Facilitated PCI
Authors Titles Year Study Type
oss et al. (51) PACT 1999 Prospective Rando
udek et al. (54) 2003 Registry
astrati et al. (61) BRAVE 2004 Prospective Rando
aioli et al. (58) 2005 Retrospective
DVANCE MI
Investigators (60)
ADVANCE MI 2005 Prospective Rando
DVANCE MI  Addressing the Value of Facilitated Angioplasty after Combinati
avarian Reperfusion Alternatives Evaluation trial; PACT  Randomized Trial Com
lanned Rescue Angioplasty in Acute Myocardial Infarction; PCI  percutaneous counting. It seems likely that the excess bleeding seen with the combined approach may have contributed to the lack of
enefit with facilitated PCI.
The initial trials showing efficacy when comparing facil-
tated PCI to thrombolytics were mostly retrospective stud-
es. Later randomized studies, such as the SIAM III,
RACIA-1, and CAPITAL AMI trials, did show benefit,
ut potentially the benefit came from the patients receiving
CI rather than from the combined approach. In fact, the
RAGUE study did show that, with transport for STEMI,
one PCI demonstrated better outcomes than either lone
hrombolytics or facilitated PCI. Perhaps these trials of
ombination therapy versus thrombolytics simply re-
emonstrated that PCI, even with the addition of throm-
olytics and the time delay with transport for PCI, provided
etter results than thrombolytics alone.
When evaluating the subsequent trials of facilitated PCI
ersus primary PCI, the largest trials showed some surrogate
mprovements, though no benefit to clinical outcomes.
any of these trials attempted to show equivalence between
acilitated PCI and primary PCI to demonstrate that, even
ith transport time or delay for on-hours interventions,
here would be equivalent results. While some of the studies
id show equivalence, the most recent and definitive study,
SSENT-4, reached adverse outcomes in its primary as
ell as secondary end points before the study had even
nrolled 50% of the planned patients. The meta-analyses
ollated the various smaller trials and showed similar results
o the ASSENT-4 trial: earlier TIMI flow grade 3 in those
atients that receive facilitated PCI, though worse clinical
utcomes and trends toward increased bleeding.
Though the results of the FINESSE trial are not yet
vailable, unless they provide convincingly contradictory
esults to the ASSENT-4 trial, the issue of thrombolytic-
acilitated PCI should be laid to rest as a theoretically
nteresting strategy that, in reality, was shown through
ultiple studies to be detrimental to the care of AMI.
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